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versus placebo. Significant improvements were evident at Week-4 and main-
tained through Week-12.
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OBJECTIVES: Few studies have evaluated the impact of GERD-symptoms on
work productivity and no French data are available. The aim of this study was to
evaluate the impact of GERD typical symptoms on work productivity and daily
activities in patients with nocturnal compared to diurnal symptoms. METHODS:
A prospective, multicenter, observational study was carried out in French pri-
mary care setting. Each physician had to include the first two consecutive adult
patients on full-time job who had experienced GERD typical symptoms at least
once during the 7 days/nights preceding the inclusion visit: 1 with exclusively
diurnal symptoms and 1 with nocturnal symptoms. Data collected by physi-
cians were: patients’ characteristics, symptomatology and treatments. Work
productivity loss was assessed using the validated self-administered Work Pro-
ductivity and Activity Impairment questionnaire specific to GERD (WPAI-GERD).
Predictors of work productivity loss were identified by multivariate regression
models and its cost estimated. RESULTS: A total of 407 physicians included 716
eligible patients: 50.8% with nocturnal and 49.2% with exclusive diurnal symp-
toms (EDS). The mean age was 46.3 years (SD 8.7), 62.8% were men, and 58.3% of
patients diagnosed before inclusion were treated for GERD. Work productivity
and daily activities decreased by 31.4% and 32.6%, respectively. Decrease rates
were higher in EDS-patients (p0.001 each). Work productivity impairment was
mostly due to impairment while working (presenteeism) rather than absentee-
ism. The symptoms intensity and composite intensity index, reflecting disease
severity, were identified as the main predictors of decreased work productivity.
The mean cost of work productivity loss per patient was estimated as €313/
week, also higher in EDS-patients (p0.001). CONCLUSIONS: GERD incurs high
work productivity loss which yields a substantial burden. Improving patients’
outcomes, especially in those with moderate or severe disease, with most ef-
fective tailored treatments and care management could be expected to reduce
work productivity loss and associated costs.
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OBJECTIVES: To assess average direct medical costs of treatment of consecutive
stages of HCV in Poland. METHODS: A questionnaire study in 7 medical centres
among experienced clinicians (1200 patients managed annually in total) was per-
formed. Six separate questionnaires were prepared and initially validated for de-
fined HCV health states: mild hepatitis-MiH, moderate hepatitis-MoH, compen-
sated cirrhosis-CoC, decompensated cirrhosis-DeC, hepatocellular carcinoma-
HCC and post liver transplant phase–1st (PLT1) and 2nd(PLT2) year of follow-up.
Each professional was asked for describing a typical procedures set conducted in
an theoretical average patient in specified chronic hepatitis C health state. The
procedures sets consisted of a few main categories: hospitalisation, ambulatory
care, diagnostic procedures, pharmacotherapy, rehabilitation, adequately to dis-
ease phase and in accordance with official procedures lists published by National
Health Fund for 2011. Antiviral treatment was excluded from the analysis.
RESULTS: Five questionnaires for each of mild hepatitis, moderate hepatitis, com-
pensated cirrhosis, decompensated cirrhosis, and two for HCC and post liver trans-
plant health states, were obtained. Calculated mean annual costs of defined health
states and their relation to the cost of liver transplantation in Poland (200000PLN
48000€ in 2010) are as follow: MiH with SVR–422PLN (99€), 0,2%; MoH with SVR–
800PLN (188€), 0,4%; CoC with SVR–2018PLN (475€), 1,0%; MiH no SVR–2384PLN
(561€), 1,2%; MoH no SVR–3097PLN (729€), 1,5%; CoC no SVR–4995PLN (1175 €), 2,4%;
DeC–14860PLN (3496€), 7,3%; HCC–38927PLN (9159€), 19,0%; PLT1–30626PLN (7206€),
15,0%; PLT2–19973PLN (4699€), 9,8%. CONCLUSIONS: There is a marked increase of
mean annual costs of standard treatment of HCV patients along with disease stage.
Assuming that in Poland about 700000 individuals can be infected with HCV, most
of them being unaware of the disease, high costs of complications of chronic hep-
atitis-C are serious social and economic burden. National screening programme
with effective antiviral treatment at early stages of disease can reduce this negative
impact on society.
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OBJECTIVES: To understand resource utilization and costs associated with refer-
rals and testing for patients with irritable bowel syndrome with constipation
(IBS-C) based on treatment response. METHODS: A web-based survey was con-
ducted for a sample of primary care physicians (PCPs) and gastroenterologists (GEs)
across different US regions. The survey captured data on referral patterns (to/from
gastroenterologists), test/procedure ordering, and follow-up physician visits for
typical patients who did and did not achieve a satisfactory relief of symptoms to a
recent treatment for IBS-C (“response”). Survey items included questions regarding
the proportion of patients who would receive tests/procedures and follow-up phy-
sician visits. Health care costs were estimated by applying associated unit costs
(derived from the 2012 Medicare physician payment schedule) to the correspond-
ing utilization. All patients were assumed to begin treatment with PCPs. The cost of
treatment failure was defined as the cost difference between physician-deemed
non-responders and responders, incorporating both PCP work-up costs and the
costs of referrals to GEs. RESULTS: Twenty PCPs and 21 GEs completed the survey.
Mean monthly number of adults treated by the physicians was 61. Most non-re-
sponders (median: 80%; mean: 72%) would be referred to a GE by PCPs. Non-re-
sponders would be more likely to receive a test/procedure compared to responders
(median: 75 vs. 0% for PCPs; 50 vs. 0% for GEs; mean: 65 vs. 10% for PCPs; 56 vs. 33%
for GEs). Thyroid function tests, complete blood count, and colonoscopy were the
most common tests/procedures that would be ordered, by both PCPs and GEs. The
median (mean) expected cost of treatment failure was estimated to be $825 ($613).
CONCLUSIONS: Not responding to treatment may result in referral to a specialist
and/or additional testing and procedures, which may lead to higher health care
resource use and costs among patients with IBS-C, a finding of potential interest to
payers.
GASTROINTESTINAL DISORDERS - Patient-Reported Outcomes & Patient
Preference Studies
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OBJECTIVES: To assess the impact of treatment response on quality of life (QOL)
and work productivity for patients with irritable bowel syndrome with constipation
(IBS-C). METHODS: Irritable Bowel Syndrome - QOL (IBS-QOL) score, EQ-5D index
score, work productivity, and IBS symptom relief were collected in two phase III
randomized placebo-controlled clinical trials of linaclotide, an investigational
treatment for IBS-C. Treatment response for IBS-C was defined as (1) a  14-point
increase at Week 12 from baseline on the overall IBS-QOL score or (2) moderately or
significantly relieved on a seven-point Likert scale on global symptom relief for 2
out of 3 months. Hours of work missed due to IBS-C were collected using the Work
Productivity and Activity Impairment (WPAI) Questionnaire. Data from the intent-
to-treat populations were pooled for linaclotide and placebo across two trials.
EQ-5D index score and work productivity were evaluated among responders and
non-responders. RESULTS: Patients were analyzed with available EQ-5D and IBS-
QOL data (n1,487) and available EQ-5D and IBS symptom relief data (n1,558),
with response rates of 46% and 14% respectively. Patients were analyzed with
available WPAI and IBS-QOL data (n1,056) and WPAI and IBS symptom relief data
(n1,103), with response rates of 47% and 15%, respectively. Responders had sta-
tistically significantly higher EQ-5D scores at Week 12 than non-responders, for
both definitions (IBS-QOL: 0.85 vs. 0.81, IBS symptom relief: 0.91 vs. 0.81, both
P0.05). Responders were statistically significantly less likely to miss 1 hour of
work during 12 weeks for IBS-C (IBS-QOL: 16.0% vs. 21.7%, IBS symptom relief: 9.6%
vs. 20.8%, both P0.05). CONCLUSIONS: Improvements in disease-specific mea-
sures correlate with improvements in health utilities and reduced work absentee-
ism among patients with IBS-C.
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OBJECTIVES:Despite Italy has a large HCV infected pool (1.500.000 estimated) novel
Direct Antiviral Agents (DAAs) against HCV genotype 1 have not yet been approved.
As the estimated budget to cover all eligible patients could be ten-fold higher,
limitations or patient selections could be applied. The study purpose is to obtain
the patients’point of view about associated costs, sustainability, possible scenarios
related to the lack of economic resources. METHODS: EpaC is the most important
Italian NGO for HCV patients. An anonymous web-based questionnaire was pub-
lished on the association website www.epac.it. It was composed of multiple choice
questions and was preceded by a scenario reporting a mean drug cost per patient
per course of 25.000-35.000 €, the availability of interferon-free monotherapy DAAs
drugs in the nearest future, different reimbursement possibilities (payment-by-
results, expenditure thresholds . . .). RESULTS: A total of 763 patients participated
the survey and 727 questionnaires were considered validly compiled. The profile of
the participants was assessed concerning sex, age, geographical provenience,
health condition, fibrosis stage, eligibility for triple treatment. 83% of patients
claimed equity of access independently of disease severity, 55% is not inclined to
postpone the treatment despite 62% of these has low/medium fibrosis, 77% of
participants does not tolerate the lack of resources that could lead to patient se-
lection, 40% is disposed to travel anywhere to get the most appropriate therapy.
CONCLUSIONS: This was a unique and the largest survey on Italian patients about
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